TY - JOUR
T1 - Morbidity and mortality in patients with posterior circulation aneurysms treated with the pipeline embolization device
T2 - A subgroup analysis of the international retrospective study of the pipeline embolization device
AU - Lopes, Demetrius K.
AU - Jang, Dong Kyu
AU - Cekirge, Saruhan
AU - Fiorella, David
AU - Hanel, Ricardo A.
AU - Kallmes, David F.
AU - Levy, Elad I.
AU - Lylyk, Pedro
N1 - Funding Information:
This study was funded by Medtronic Inc. Dr Lopes is a consultant for Covidien, Stryker, and Penumbra, and is on the advisory board of Siemens Medical Solutions. Dr Cekirge is a consultant/speaker for Medtronic, Microvention, and Sequent. Dr Fiorella is a consultant for Medtronic (proctor PED), J&J/Codman, Microvention, Sequent, and Penumbra; receives royalties from J&J/Codman; has a patent (planned, pending, or issued) with Vascular Simulators; and institutional grants from Microvention, Sequent, and Penumbra. Dr Hanel is a consultant for Medtronic. Dr Kallmes is PI of the PED trial and is a CEC member, has received institutional funding for his membership of the cost-effectiveness board at GE Healthcare and grants from Microvention (pre-/clinical research), Codman, NeuroSigma, Sequent, and Surmodics (preclinical). Dr Levy has received honoraria (training/lectures) from Medtronic, is a shareholder/has
Publisher Copyright:
Copyright © 2018 by the Congress of Neurological Surgeons.
PY - 2018/9/1
Y1 - 2018/9/1
N2 - Background: The safety of PipelineTM Embolization Device (PED;Medtronic Inc, Dublin, Ireland) in posterior circulation aneurysms is still controversial. Objective: To study complications associated with the treatment of posterior circulation aneurysms by conducting a subgroup analysis from the International Retrospective Study of PED registry. Methods: Data from 91 consecutive patients with 95 posterior circulation aneurysms at 17 centers between July 2008 to February 2013 were analyzed. The primary endpoint was defined as any complication leading to neurological morbidity or death. The outcome predictors were calculated using Kaplan.Meier and Cox regression methods. Results: The mean aneurysm size was 13.8 mm. Aneurysm types were saccular (36.8%), fusiform (29.5%), dissecting (28.4%), and others (5.3%). The median follow-up was 21.1 mo. Twelve (13.2%) patients encountered a primary endpoint event. In multivariate analysis for the primary endpoint, use of ≥3 PEDs and fusiform shape compared with other shapes had hazard ratios (HRs) of 7.77 (95% confidence interval [CI], 2.48-25.86; P=.0007) and 3.48 (95% CI, 1.06-13.39; P=.0488), respectively. Themultivariate HR of aneurysmsize for neurological morbidity after PED implantation was 1.11 (95% CI, 1.04-1.18; P = .0015), and HRs of ruptured aneurysm and age for neurologicalmortality were 8.1 (95% CI, 1.31-41.26; P = .0197) and 1.07 (95% CI, 1.02-1.15; P = .0262), respectively. Basilar artery aneurysm had an HR of 3.54 (95% CI, 1.12-14.18, P = .0529) in the univariate analysis for major outcomes. Conclusion: PED implantation may be considered for the treatment of posterior circulation aneurysms, especially of saccular or dissecting type. Ourmajor complications appear to be comparable to those reported previously after clipping and coiling in the literature. Neurointerventionists should consider the shape, size, rupture, and location of complex posterior circulation aneurysms aswell as age and PED number before the PED placement.
AB - Background: The safety of PipelineTM Embolization Device (PED;Medtronic Inc, Dublin, Ireland) in posterior circulation aneurysms is still controversial. Objective: To study complications associated with the treatment of posterior circulation aneurysms by conducting a subgroup analysis from the International Retrospective Study of PED registry. Methods: Data from 91 consecutive patients with 95 posterior circulation aneurysms at 17 centers between July 2008 to February 2013 were analyzed. The primary endpoint was defined as any complication leading to neurological morbidity or death. The outcome predictors were calculated using Kaplan.Meier and Cox regression methods. Results: The mean aneurysm size was 13.8 mm. Aneurysm types were saccular (36.8%), fusiform (29.5%), dissecting (28.4%), and others (5.3%). The median follow-up was 21.1 mo. Twelve (13.2%) patients encountered a primary endpoint event. In multivariate analysis for the primary endpoint, use of ≥3 PEDs and fusiform shape compared with other shapes had hazard ratios (HRs) of 7.77 (95% confidence interval [CI], 2.48-25.86; P=.0007) and 3.48 (95% CI, 1.06-13.39; P=.0488), respectively. Themultivariate HR of aneurysmsize for neurological morbidity after PED implantation was 1.11 (95% CI, 1.04-1.18; P = .0015), and HRs of ruptured aneurysm and age for neurologicalmortality were 8.1 (95% CI, 1.31-41.26; P = .0197) and 1.07 (95% CI, 1.02-1.15; P = .0262), respectively. Basilar artery aneurysm had an HR of 3.54 (95% CI, 1.12-14.18, P = .0529) in the univariate analysis for major outcomes. Conclusion: PED implantation may be considered for the treatment of posterior circulation aneurysms, especially of saccular or dissecting type. Ourmajor complications appear to be comparable to those reported previously after clipping and coiling in the literature. Neurointerventionists should consider the shape, size, rupture, and location of complex posterior circulation aneurysms aswell as age and PED number before the PED placement.
KW - Aneurysm
KW - Complications
KW - Fusiform
KW - Pipeline
KW - Posterior circulation
UR - http://www.scopus.com/inward/record.url?scp=85055482666&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055482666&partnerID=8YFLogxK
U2 - 10.1093/neuros/nyx467
DO - 10.1093/neuros/nyx467
M3 - Article
C2 - 28945879
AN - SCOPUS:85055482666
SN - 0148-396X
VL - 83
SP - 488
EP - 500
JO - Neurosurgery
JF - Neurosurgery
IS - 3
ER -